Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial

A C Vilmar; E Santoni-Rugiu; J B Sorensen

doi:10.1093/annonc/mds335

Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial

A C Vilmar, E Santoni-Rugiu, J B Sorensen

Afdeling for Patologi DIA

20 Citationer (Scopus)

Abstract

Platinum-based doublets (PBDs) remain the cornerstone of treatment in non-small-cell lung cancer (NSCLC) and may include gemcitabine. A biomarker predicting sensitivity to this antimetabolite would represent a major step forward. Accordingly, we explored the predictive role of ribonucleotide reductase subunit M (RRM1) in advanced NSCLC.

Originalsprog	Engelsk
Tidsskrift	Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
Vol/bind	24
Udgave nummer	2
Sider (fra-til)	309-14
Antal sider	6
ISSN	0923-7534
DOI	https://doi.org/10.1093/annonc/mds335
Status	Udgivet - feb. 2013

Adgang til dokumentet

10.1093/annonc/mds335

Andre filer og links

Link to publication in Scopus

Citationsformater

Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial. / Vilmar, A C; Santoni-Rugiu, E; Sorensen, J B.
I: Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, Bind 24, Nr. 2, 02.2013, s. 309-14.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

@article{b4b82967d3914b39ab7494372cd3e2c9,

title = "Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial",

abstract = "Platinum-based doublets (PBDs) remain the cornerstone of treatment in non-small-cell lung cancer (NSCLC) and may include gemcitabine. A biomarker predicting sensitivity to this antimetabolite would represent a major step forward. Accordingly, we explored the predictive role of ribonucleotide reductase subunit M (RRM1) in advanced NSCLC.",

keywords = "Adult, Aged, Antineoplastic Agents, Phytogenic, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cisplatin, Deoxycytidine, Disease-Free Survival, Female, Humans, Lung Neoplasms, Male, Middle Aged, Paclitaxel, Prognosis, Radiation-Sensitizing Agents, Survival Rate, Tumor Markers, Biological, Tumor Suppressor Proteins, Vinblastine, Young Adult",

author = "Vilmar, \{A C\} and E Santoni-Rugiu and Sorensen, \{J B\}",

year = "2013",

month = feb,

doi = "10.1093/annonc/mds335",

language = "English",

volume = "24",

pages = "309--14",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology / ESMO",

issn = "0923-7534",

publisher = "Elsevier Limited",

number = "2",

}

TY - JOUR

T1 - Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial

AU - Vilmar, A C

AU - Santoni-Rugiu, E

AU - Sorensen, J B

PY - 2013/2

Y1 - 2013/2

N2 - Platinum-based doublets (PBDs) remain the cornerstone of treatment in non-small-cell lung cancer (NSCLC) and may include gemcitabine. A biomarker predicting sensitivity to this antimetabolite would represent a major step forward. Accordingly, we explored the predictive role of ribonucleotide reductase subunit M (RRM1) in advanced NSCLC.

AB - Platinum-based doublets (PBDs) remain the cornerstone of treatment in non-small-cell lung cancer (NSCLC) and may include gemcitabine. A biomarker predicting sensitivity to this antimetabolite would represent a major step forward. Accordingly, we explored the predictive role of ribonucleotide reductase subunit M (RRM1) in advanced NSCLC.

KW - Adult

KW - Aged

KW - Antineoplastic Agents, Phytogenic

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Carcinoma, Non-Small-Cell Lung

KW - Cisplatin

KW - Deoxycytidine

KW - Disease-Free Survival

KW - Female

KW - Humans

KW - Lung Neoplasms

KW - Male

KW - Middle Aged

KW - Paclitaxel

KW - Prognosis

KW - Radiation-Sensitizing Agents

KW - Survival Rate

KW - Tumor Markers, Biological

KW - Tumor Suppressor Proteins

KW - Vinblastine

KW - Young Adult

UR - https://www.scopus.com/pages/publications/84873800406

U2 - 10.1093/annonc/mds335

DO - 10.1093/annonc/mds335

M3 - Journal article

C2 - 23038758

SN - 0923-7534

VL - 24

SP - 309

EP - 314

JO - Annals of oncology : official journal of the European Society for Medical Oncology / ESMO

JF - Annals of oncology : official journal of the European Society for Medical Oncology / ESMO

IS - 2

ER -

Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater